ArticleLeukemia2018
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
Abstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Article
- Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency.Nature communications · 2025Article
- A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Intermediately Methylated Regions in Normal Cells Are Epimutation Hotspots in Cancer.bioRxiv : the preprint server for biology · 2025Article
- GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome.Blood cancer journal · 2025Article
- PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Linking GATA2 to myeloid dysplasia and complex cytogenetics in adult myelodysplastic neoplasm and acute myeloid leukemia.Blood advances · 2024Article
- Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.International journal of molecular sciences · 2024Review
- Gata2 noncoding genetic variation as a determinant of hematopoietic stem/progenitor cell mobilization efficiency.Blood advances · 2023Article
- A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins.Blood advances · 2023Article
- TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.Nature communications · 2023Article
- Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency.Haematologica · 2023Article
- Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.Haematologica · 2023Article
- Pathogenic human variant that dislocates GATA2 zinc fingers disrupts hematopoietic gene expression and signaling networks.The Journal of clinical investigation · 2023Article
- The spectrum of GATA2 deficiency syndrome.Blood · 2023Article
- Review
- GATA2 deficiency elevates interferon regulatory factor-8 to subvert a progenitor cell differentiation program.Blood advances · 2022Article
- ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Ahad F Al SeraihiCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. a.f.h.alseraihi@qmul.ac.uk.
Ana Rio-MachinCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Kiran TawanaCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Csaba BödörMTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0002-0729-692X
Jun WangCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0003-2509-9599
Ai NaganoCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
James A HewardCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Sameena IqbalCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Steven BestLaboratory for Molecular Haemato-Oncology, King's College Hospital NHS Foundation Trust, London, UK.
Nicholas LeaLaboratory for Molecular Haemato-Oncology, King's College Hospital NHS Foundation Trust, London, UK.
Donal McLornanDepartment of Haematological Medicine, King's College Hospital, London, UK.
Emilia J KozyraUniversity of Freiburg, Faculty of Biology, Freiburg, Germany.
Marcin W WlodarskiPediatric Hematology and Oncology, University Children's Hospital Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-6638-9643
Charlotte M NiemeyerPediatric Hematology and Oncology, University Children's Hospital Freiburg, Freiburg, Germany.
Hamish ScottCentre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, Australia.
Chris HahnCentre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0001-5105-2554
Alicia EllisonCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.
Hemanth TummalaCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.
Shirleny Romualdo CardosoCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.
Tom VulliamyCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.
Inderjeet DokalCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK.
Tom ButlerDepartment of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Matthew SmithDepartment of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Jamie CavenaghDepartment of Haemato-Oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Jude FitzgibbonCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. j.fitzgibbon@qmul.ac.uk.
Funding
Medical Research Council G0700052
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultFemaleGATA2 Transcription FactorGerm-Line MutationHumansLeukemia, Myeloid, AcuteMalePedigreePenetranceYoung AdultGATA2 protein, humanGATA2 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.